Results 1 to 10 of about 149 (146)
Preferential Cochleotoxicity of Cisplatin [PDF]
Frontiers in Neuroscience, 2021 Cisplatin-induced ototoxicity in humans is more predominant in the cochlea than in the vestibule. Neither definite nor substantial vestibular dysfunction after cisplatin treatment has been consistently reported in the current literature. Inner ear hair cells seem to have intrinsic characteristics that make them susceptible to direct exposure to ...
Pattarawadee Prayuenyong +6 more
openaire +5 more sources
Cisplatin ototoxicity histopathology [PDF]
Laryngoscope Investigative Otolaryngology, 2021 This study investigates the histopathological changes of the cochlea and vestibular end organs of a patient who received cisplatin for Hodgkin's lymphoma. He experienced acute high-frequency sensorineural hearing loss and tinnitus after receiving treatment.
Sarah E. Hodge +3 more
openaire +6 more sources
International Journal of Gynecological Cancer, 2020 We thank our colleagues[1][1] for the questions regarding cisplatin in electrochemotherapy in the skin and mucosal lesions of the vulva and vagina. The choice of drug (bleomycin or cisplatin) has been a topic on which we have reflected for a long time since the first results published in 2013[2][2]
Perrone A. M., Corrado G., De Iaco P.
openaire +3 more sources
Mechanisms of Cisplatin Nephrotoxicity [PDF]
Toxins, 2010 Cisplatin is a widely used and highly effective cancer chemotherapeutic agent. One of the limiting side effects of cisplatin use is nephrotoxicity. Research over the past 10 years has uncovered many of the cellular mechanisms which underlie cisplatin-induced renal cell death.
Ronald P. Miller +3 more
openaire +4 more sources
, 2005 Cisplatin nanocapsules represent a novel lipid formulation of the anticancer drug cis-diamminedichloroplatinum(II), in which nanoprecipitates of cisplatin are covered by a phospholipid bilayer coat consisting of an equimolar mixture of phosphatidylcholine and phosphatidylserine.
de Kroon, A.I.P.M. +3 more
openaire +4 more sources
Treatment of unresectable or metastatic osteosarcoma with cisplatin or cisplatin–doxorubicin [PDF]
Cancer, 1985 Responses and toxicity after treatment with cisplatin and cisplatin-doxorubicin were compared in two groups of patients with unresectable or metastatic osteosarcoma. Complete or partial responses developed in 3 of 18 individuals treated with cisplatin, and in 5 of 19 after the two-drug combination.
Charles B. Pratt +7 more
openaire +3 more sources
Chemistry & Biology, 2010 In order to form a covalent complex with DNA inside human cells, cisplatin has to overcome the protective environment of a nucleosome, where DNA is complexed with histone proteins. Todd and Lippard (2010) expand our understanding of this process by describing the structure of a nucleosome containing a Pt-DNA adduct, which has important implications for
openaire +3 more sources
The Molecular Perspective: Cisplatin [PDF]
Stem Cells, 2006 Learning Objective After completing this course, the reader will be able to: Describe the structure and action of cisplatin. Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com
openaire +4 more sources
Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma [PDF]
New England Journal of Medicine, 2009 Preoperative cisplatin alone may be as effective as cisplatin plus doxorubicin in standard-risk hepatoblastoma (a tumor involving three or fewer sectors of the liver that is associated with an alpha-fetoprotein level of >100 ng per milliliter).Children with standard-risk hepatoblastoma who were younger than 16 years of age were eligible for inclusion ...
PERILONGO, GIORGIO +18 more
openaire +5 more sources
Cisplatin Toxicity in Cats [PDF]
Journal of Veterinary Internal Medicine, 1987 Cisplatin (cis‐diamminedichloroplatinum; Platinol, Bristol, Syracuse, NY) was administered to 11 cats, divided into three groups of experimental and clinical patients. In group 1, cisplatin was administered at a dose of 60 mg/m2 to four cats. In an attempt to avoid renal toxicity, saline diuresis was induced by administering 0.9% saline solution ...
Deborah W. Knapp +4 more
openaire +3 more sources